Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia

• Conditions: Pneumonitis; Coronavirus Infection
• Interventions: Drug: Plaquenil 200Mg Tablet

• Registration Number: NCT04326725
• Lead Sponsor: Istinye University

Brief Summary

Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminC including zinc once a day were included in the study. Study has conducted on 20th of march. Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients in Ankara.

Detailed Description

Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminC including zinc once a day were included in the study. Study has conducted on 20th of march. Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients.PArticipants, age, sex, BMI, smoking history, comorbid disease were also registered.

Study Timeline

• Study Start: 2020-03-20
• Study First Submitted: 2020-03-26
• Study First Submitted QC: 2020-03-27
• Study First Posted: 2020-03-30
• Status Verified: 2020-07
• Primary Completion: 2020-07-01
• Last Update Submitted: 2020-07-27
• Last Update Posted: 2020-07-28
• Study Completion: 2020-09-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. person who are working as health professional with contact to known COVID positive case
2. Their first degree relatives (child, spouse or parents)
3. must be able to swallow tablets

Read More

Exclusion Criteria

1. Already using plaquenil for other reasons (RA etc)
2. person with the diagnosis of COVID infection
3. Person with the condition may cause complications with this medication (severe CVD, av block, already has ophtalmological complications, organ failure of any degree etc).
4. Documented allergic history to chloroquine;
5. Documented history of hematological system diseases;
6. Documented history of chronic liver and kidney diseases;
7. Documented history of cardiac arrhythmia or chronic heart diseases;
8. Documented history of retina or hearing dysfunction;
9. Documented history of mental illnesses; 10. Use of digitalis due to the previous disease.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Hydroxychloroquine	Plaquenil 200Mg Tablet	Subjects with prophylaxis

Primary Outcome Measures

Name	Time	Method
Protection against COVID-19	4 months	persons who took this medication should not have an infection

Trial Locations

Locations (1)

Istinye University Medical School; 🇹🇷 Istanbul, Turkey